Skip to main content
Erschienen in:

01.03.2007 | Leitthema

Antikörpertherapie in klinischer und präklinischer Anwendung bei gastrointestinalen Karzinomen

verfasst von: Dr. A. Thalheimer, S. Braendlein, P. Vollmers, A. Thiede, D. Meyer, B. Illert

Erschienen in: Die Onkologie | Ausgabe 3/2007

Einloggen, um Zugang zu erhalten

Zusammenfassung

Derzeit befinden sich viele neue Substanzen zur Therapie gastrointestinaler Karzinome in klinischer und präklinischer Anwendung. Die Apoptose von malignen Zellen als natürliche Form der Zellzerstörung stellt ein ideales Ziel in der Krebstherapie dar. Die tatsächliche Effektivität und das Nebenwirkungsspektrum bisheriger Antikörper sind gegenwärtig von einer überzeugenden klinischen Anwendung zu weit entfernt. Verschiedene Substanzklassen von Antikörpern geben aber Hoffnung, dass in naher Zukunft die Verträglichkeit durch veränderte Herstellung (Humanisierung, Chimärisation oder komplett humane Antikörper) und die Wirkung durch höhere Selektivität substanziell verbessert werden.
Durch den Einsatz neuer Zytostatika und die Entwicklung zielgerichteter Antikörper gegen EGFR und VEGF konnte das mediane Überleben bei Patienten mit gastrointestinalen Karzinomen in den letzten Jahren deutlich verlängert werden. Insbesondere das Überleben von Patienten mit fortgeschrittenen kolorektalen Karzinomen konnte auf aktuell über 2 Jahre verlängert und damit im Vergleich zur 5-FU-Ära fast verdoppelt werden. Die vielfältigen Kombinationstherapien mit Chemotherapeutika und monoklonalen Antikörpern machen die Behandlung von Patienten mit gastrointestinalen Karzinomen zwar deutlich komplexer als früher, bieten aber gerade Patienten mit Metastasen wesentlich effektivere Therapieansätze. Bevacizumab und Cetuximab als Paradebeispiele der „targeted therapy“ haben innerhalb klinischer Studien in der Erst- und Zweitlinientherapie des metastasierten kolorektalen Karzinoms berechtigterweise Einzug gehalten.
Literatur
1.
Zurück zum Zitat Akbulut H, Altuntas F, Akbulut KG et al. (2002) Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 20: 184–190CrossRefPubMed Akbulut H, Altuntas F, Akbulut KG et al. (2002) Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma. Cytokine 20: 184–190CrossRefPubMed
2.
Zurück zum Zitat Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29: 3–9CrossRef Arteaga CL (2002) Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol 29: 3–9CrossRef
3.
Zurück zum Zitat Baselga J (2001) The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer (Suppl 4) 37: S16–S22 Baselga J (2001) The EGFR as a target for anticancer therapy--focus on cetuximab. Eur J Cancer (Suppl 4) 37: S16–S22
4.
Zurück zum Zitat Becker JC, Muller-Tidow C, Serve H et al. (2006) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297–3305PubMed Becker JC, Muller-Tidow C, Serve H et al. (2006) Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12: 3297–3305PubMed
5.
Zurück zum Zitat Boes M (2000) Role of natural and immune IgM antibodies in immune responses. Mol Immunol 37: 1141–1149CrossRefPubMed Boes M (2000) Role of natural and immune IgM antibodies in immune responses. Mol Immunol 37: 1141–1149CrossRefPubMed
6.
7.
Zurück zum Zitat Brandlein S, Beyer I, Eck M et al. (2003) Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res 63: 2052–2061PubMed Brandlein S, Beyer I, Eck M et al. (2003) Cysteine-rich fibroblast growth factor receptor 1, a new marker for precancerous epithelial lesions defined by the human monoclonal antibody PAM-1. Cancer Res 63: 2052–2061PubMed
8.
Zurück zum Zitat Brandlein S, Pohle T, Ruoff N et al. (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995–8005PubMed Brandlein S, Pohle T, Ruoff N et al. (2003) Natural IgM antibodies and immunosurveillance mechanisms against epithelial cancer cells in humans. Cancer Res 63: 7995–8005PubMed
9.
Zurück zum Zitat Brandlein S, Pohle T, Vollmers C et al. (2004) CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 11: 777–784PubMed Brandlein S, Pohle T, Vollmers C et al. (2004) CFR-1 receptor as target for tumor-specific apoptosis induced by the natural human monoclonal antibody PAM-1. Oncol Rep 11: 777–784PubMed
10.
Zurück zum Zitat Brandlein S, Vollmers HP (2004) Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 19: 897–905PubMed Brandlein S, Vollmers HP (2004) Natural IgM antibodies, the ignored weapons in tumour immunity. Histol Histopathol 19: 897–905PubMed
12.
13.
Zurück zum Zitat Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I (1987) Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA 84: 4538–4542CrossRefPubMed Chaudhary VK, FitzGerald DJ, Adhya S, Pastan I (1987) Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin. Proc Natl Acad Sci USA 84: 4538–4542CrossRefPubMed
14.
Zurück zum Zitat Ciardiello F, Caputo R, Troiani T et al. (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93: 172–178CrossRefPubMed Ciardiello F, Caputo R, Troiani T et al. (2001) Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines. Int J Cancer 93: 172–178CrossRefPubMed
15.
Zurück zum Zitat Cohen BD, Baker DA, Soderstrom C et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063–2073CrossRefPubMed Cohen BD, Baker DA, Soderstrom C et al. (2005) Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 11: 2063–2073CrossRefPubMed
16.
Zurück zum Zitat Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20CrossRefPubMed Cunningham D, Allum WH, Stenning SP et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355: 11–20CrossRefPubMed
17.
Zurück zum Zitat Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed Cunningham D, Humblet Y, Siena S et al. (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337–345CrossRefPubMed
18.
Zurück zum Zitat Gramont A de, Bosset JF, Milan C et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815PubMed Gramont A de, Bosset JF, Milan C et al. (1997) Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808–815PubMed
19.
Zurück zum Zitat Egea G, Franci C, Gambus G et al. (1993) cis-Golgi resident proteins and O-glycans are abnormally compartmentalized in the RER of colon cancer cells. J Cell Sci 105: 819–830PubMed Egea G, Franci C, Gambus G et al. (1993) cis-Golgi resident proteins and O-glycans are abnormally compartmentalized in the RER of colon cancer cells. J Cell Sci 105: 819–830PubMed
20.
Zurück zum Zitat Ellerbroek SM, Halbleib JM, Benavidez M et al. (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855–1861PubMed Ellerbroek SM, Halbleib JM, Benavidez M et al. (2001) Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association. Cancer Res 61: 1855–1861PubMed
21.
Zurück zum Zitat Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595–27602PubMed Fan Z, Lu Y, Wu X, Mendelsohn J (1994) Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A431 squamous carcinoma cells. J Biol Chem 269: 27595–27602PubMed
22.
Zurück zum Zitat Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676CrossRefPubMed Ferrara N, Gerber HP, LeCouter J (2003) The biology of VEGF and its receptors. Nat Med 9: 669–676CrossRefPubMed
23.
Zurück zum Zitat Figlin RA BACJ (2002) ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 35: A37 Figlin RA BACJ (2002) ABX-EGF, a fully human anti-epidermal growth factor receptor (EGFR) monoclonal antibody in patients with advanced cancer: phase I clinical results. Proc Am Soc Clin Oncol 35: A37
24.
Zurück zum Zitat Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31PubMed Folkman J (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27–31PubMed
25.
Zurück zum Zitat Folprecht G (2004) Cetuximab/Irinotecan/high-dose-5-fluorouracil/leucovorin in the first-line therapy of metastatic colorectal cancer. Gastrointestinal Cancers Symposium: A283 Folprecht G (2004) Cetuximab/Irinotecan/high-dose-5-fluorouracil/leucovorin in the first-line therapy of metastatic colorectal cancer. Gastrointestinal Cancers Symposium: A283
26.
Zurück zum Zitat Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245–273CrossRefPubMed Fong L, Engleman EG (2000) Dendritic cells in cancer immunotherapy. Annu Rev Immunol 18: 245–273CrossRefPubMed
27.
Zurück zum Zitat Garcia I, Vizoso F, Martin A et al. (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234–241CrossRefPubMed Garcia I, Vizoso F, Martin A et al. (2003) Clinical significance of the epidermal growth factor receptor and HER2 receptor in resectable gastric cancer. Ann Surg Oncol 10: 234–241CrossRefPubMed
28.
Zurück zum Zitat Gibson MK, Abraham SC, Wu TT et al. (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9: 6461–6468PubMed Gibson MK, Abraham SC, Wu TT et al. (2003) Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy. Clin Cancer Res 9: 6461–6468PubMed
29.
Zurück zum Zitat Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6: 29–31PubMed Gibson TB, Ranganathan A, Grothey A (2006) Randomized phase III trial results of panitumumab, a fully human anti-epidermal growth factor receptor monoclonal antibody, in metastatic colorectal cancer. Clin Colorectal Cancer 6: 29–31PubMed
30.
Zurück zum Zitat Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21: 403–410CrossRefPubMed Glennie MJ, Johnson PW (2000) Clinical trials of antibody therapy. Immunol Today 21: 403–410CrossRefPubMed
31.
Zurück zum Zitat Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl 3): S25–S33CrossRef Gordon MS, Cunningham D (2005) Managing patients treated with bevacizumab combination therapy. Oncology 69 (Suppl 3): S25–S33CrossRef
32.
Zurück zum Zitat Gordon MS, Margolin K, Talpaz M et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850PubMed Gordon MS, Margolin K, Talpaz M et al. (2001) Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 19: 843–850PubMed
33.
Zurück zum Zitat Gross ME, Zorbas MA, Danels YJ et al. (1991) Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51: 1452–1459PubMed Gross ME, Zorbas MA, Danels YJ et al. (1991) Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient. Cancer Res 51: 1452–1459PubMed
34.
Zurück zum Zitat Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214CrossRefPubMed Grothey A, Sargent D, Goldberg RM, Schmoll HJ (2004) Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 22: 1209–1214CrossRefPubMed
35.
Zurück zum Zitat Gschwend JE (1996) [Apoptosis--principles and importance of programmed cell death for prostatic carcinoma]. Urologe A 35: 390–399CrossRefPubMed Gschwend JE (1996) [Apoptosis--principles and importance of programmed cell death for prostatic carcinoma]. Urologe A 35: 390–399CrossRefPubMed
36.
Zurück zum Zitat Guba M, Seeliger H, Kleespies A et al. (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19: 510–517CrossRefPubMed Guba M, Seeliger H, Kleespies A et al. (2004) Vascular endothelial growth factor in colorectal cancer. Int J Colorectal Dis 19: 510–517CrossRefPubMed
37.
Zurück zum Zitat Hanisch FG, Stadie TR, Deutzmann F, Peter-Katalinic J (1996) MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur J Biochem 236: 318–327CrossRefPubMed Hanisch FG, Stadie TR, Deutzmann F, Peter-Katalinic J (1996) MUC1 glycoforms in breast cancer--cell line T47D as a model for carcinoma-associated alterations of 0-glycosylation. Eur J Biochem 236: 318–327CrossRefPubMed
38.
Zurück zum Zitat Heinzerling JH, Huerta S (2006) Bowel perforation from Bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63: 334–337CrossRefPubMed Heinzerling JH, Huerta S (2006) Bowel perforation from Bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management. Curr Surg 63: 334–337CrossRefPubMed
39.
Zurück zum Zitat Hennemann B, Beckmann G, Eichelmann A et al. (1998) Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother 45: 250–256PubMed Hennemann B, Beckmann G, Eichelmann A et al. (1998) Phase I trial of adoptive immunotherapy of cancer patients using monocyte-derived macrophages activated with interferon gamma and lipopolysaccharide. Cancer Immunol Immunother 45: 250–256PubMed
40.
Zurück zum Zitat Hensel F, Brandlein S, Eck M et al. (2001) A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 81: 1097–1108PubMed Hensel F, Brandlein S, Eck M et al. (2001) A novel proliferation-associated variant of CFR-1 defined by a human monoclonal antibody. Lab Invest 81: 1097–1108PubMed
41.
Zurück zum Zitat Hensel F, Hermann R, Brandlein S et al. (2001) Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab Invest 81: 1553–1563PubMed Hensel F, Hermann R, Brandlein S et al. (2001) Regulation of the new coexpressed CD55 (decay-accelerating factor) receptor on stomach carcinoma cells involved in antibody SC-1-induced apoptosis. Lab Invest 81: 1553–1563PubMed
42.
Zurück zum Zitat Hensel F, Hermann R, Schubert C et al. (1999) Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res 59: 5299–5306PubMed Hensel F, Hermann R, Schubert C et al. (1999) Characterization of glycosylphosphatidylinositol-linked molecule CD55/decay-accelerating factor as the receptor for antibody SC-1-induced apoptosis. Cancer Res 59: 5299–5306PubMed
43.
Zurück zum Zitat Hochster HS, Hart LL, Ramanathan RK et al. (2006) Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. Abstract 244: ASCO 2006 Hochster HS, Hart LL, Ramanathan RK et al. (2006) Results of the TREE-2 cohort: Safety, tolerability, and efficacy of bevacizumab added to three oxaliplatin/fluoropyrimidine regimens as first-line treatment of metastatic colorectal cancer. Abstract 244: ASCO 2006
44.
Zurück zum Zitat Hosono T, Fukao T, Ogihara J et al. (2005) Diallyl trisulfide suppresses the proliferation and induces apoptosis of human colon cancer cells through oxidative modification of beta-tubulin. J Biol Chem 280: 41487–41493CrossRefPubMed Hosono T, Fukao T, Ogihara J et al. (2005) Diallyl trisulfide suppresses the proliferation and induces apoptosis of human colon cancer cells through oxidative modification of beta-tubulin. J Biol Chem 280: 41487–41493CrossRefPubMed
45.
Zurück zum Zitat Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed Hurwitz H, Fehrenbacher L, Novotny W et al. (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350: 2335–2342CrossRefPubMed
46.
Zurück zum Zitat Illert B (2004) Induction of apoptosis and tumor cell regression by SC-1, a novel therapeutic IgM antibody for the treatment of gastric carcinomas. Scientific Proceedings of the 95th AACR 45: 1017 Illert B (2004) Induction of apoptosis and tumor cell regression by SC-1, a novel therapeutic IgM antibody for the treatment of gastric carcinomas. Scientific Proceedings of the 95th AACR 45: 1017
47.
Zurück zum Zitat Illert B, Fein M, Otto C et al. (2005) Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. Scand J Gastroenterol 40: 843–849CrossRefPubMed Illert B, Fein M, Otto C et al. (2005) Disseminated tumor cells in the blood of patients with gastric cancer are an independent predictive marker of poor prognosis. Scand J Gastroenterol 40: 843–849CrossRefPubMed
48.
Zurück zum Zitat Illert B, Otto C, Vollmers HP et al. (2005) Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol Rep 13: 765–770PubMed Illert B, Otto C, Vollmers HP et al. (2005) Human antibody SC-1 reduces disseminated tumor cells in nude mice with human gastric cancer. Oncol Rep 13: 765–770PubMed
49.
Zurück zum Zitat Italiano A (2006) Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology 70: 161–167CrossRefPubMed Italiano A (2006) Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies. Oncology 70: 161–167CrossRefPubMed
50.
Zurück zum Zitat Jo M, Kim TH, Seol DW et al. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564–567CrossRefPubMed Jo M, Kim TH, Seol DW et al. (2000) Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med 6: 564–567CrossRefPubMed
51.
Zurück zum Zitat Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65CrossRefPubMed Kabbinavar F, Hurwitz HI, Fehrenbacher L et al. (2003) Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 21: 60–65CrossRefPubMed
52.
Zurück zum Zitat Kang SM, Maeda K, Onoda N et al. (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74: 502–507CrossRefPubMed Kang SM, Maeda K, Onoda N et al. (1997) Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis. Int J Cancer 74: 502–507CrossRefPubMed
53.
Zurück zum Zitat Khorana AA, Ryan CK, Cox C et al. (2003) Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97: 960–968CrossRefPubMed Khorana AA, Ryan CK, Cox C et al. (2003) Vascular endothelial growth factor, CD68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis. Cancer 97: 960–968CrossRefPubMed
54.
Zurück zum Zitat Koenders PG, Peters WH, Wobbes T et al. (1992) Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 65: 189–192PubMed Koenders PG, Peters WH, Wobbes T et al. (1992) Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue. Br J Cancer 65: 189–192PubMed
55.
Zurück zum Zitat Kohne CH, Folprecht G (2004) Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol (Suppl 4) 15: iv43–iv53 Kohne CH, Folprecht G (2004) Current perspectives in the treatment of metastatic colorectal cancer. Ann Oncol (Suppl 4) 15: iv43–iv53
56.
Zurück zum Zitat Kountouras J, Zavos C, Chatzopoulos D (2005) Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol 90: 249–259CrossRefPubMed Kountouras J, Zavos C, Chatzopoulos D (2005) Apoptotic and anti-angiogenic strategies in liver and gastrointestinal malignancies. J Surg Oncol 90: 249–259CrossRefPubMed
57.
Zurück zum Zitat Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748–753CrossRefPubMed Lee JC, Chow NH, Wang ST, Huang SM (2000) Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients. Eur J Cancer 36: 748–753CrossRefPubMed
58.
Zurück zum Zitat Lin YS, Nguyen C, Mendoza JL et al. (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371–378PubMed Lin YS, Nguyen C, Mendoza JL et al. (1999) Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor. J Pharmacol Exp Ther 288: 371–378PubMed
59.
Zurück zum Zitat Lockhart AC, Berlin JD (2005) The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32: 52–60CrossRefPubMed Lockhart AC, Berlin JD (2005) The epidermal growth factor receptor as a target for colorectal cancer therapy. Semin Oncol 32: 52–60CrossRefPubMed
60.
Zurück zum Zitat Lode HN, Reisfeld RA (2000) Targeted cytokines for cancer immunotherapy. Immunol Res 21: 279–288CrossRefPubMed Lode HN, Reisfeld RA (2000) Targeted cytokines for cancer immunotherapy. Immunol Res 21: 279–288CrossRefPubMed
61.
Zurück zum Zitat MacPherson G, Kushnir N, Wykes M (1999) Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 172: 325–334CrossRefPubMed MacPherson G, Kushnir N, Wykes M (1999) Dendritic cells, B cells and the regulation of antibody synthesis. Immunol Rev 172: 325–334CrossRefPubMed
62.
Zurück zum Zitat Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 15: 3266–3274PubMed Maloney DG, Grillo-Lopez AJ, Bodkin DJ et al. (1997) IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin’s lymphoma. J Clin Oncol 15: 3266–3274PubMed
63.
Zurück zum Zitat Marini P, Denzinger S, Schiller D et al. (2006) Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145–5154PubMed Marini P, Denzinger S, Schiller D et al. (2006) Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo. Oncogene 25: 5145–5154PubMed
64.
Zurück zum Zitat Martin F, Kearney JF (2000) Selection in the mature B cell repertoire. Curr Top Microbiol Immunol 252: 97–105PubMed Martin F, Kearney JF (2000) Selection in the mature B cell repertoire. Curr Top Microbiol Immunol 252: 97–105PubMed
65.
Zurück zum Zitat Matsukawa H, Kanai T, Naganuma M et al. (2005) A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol 40: 945–955CrossRefPubMed Matsukawa H, Kanai T, Naganuma M et al. (2005) A novel apoptosis-inducing monoclonal antibody (anti-LHK) against a cell surface antigen on colon cancer cells. J Gastroenterol 40: 945–955CrossRefPubMed
66.
Zurück zum Zitat Matsumoto M, Natsugoe S, Okumura H et al. (2006) Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg 10: 1016–1022CrossRefPubMed Matsumoto M, Natsugoe S, Okumura H et al. (2006) Overexpression of vascular endothelial growth factor-C correlates with lymph node micrometastasis in submucosal esophageal cancer. J Gastrointest Surg 10: 1016–1022CrossRefPubMed
67.
Zurück zum Zitat McKay JA, Murray LJ, Curran S et al. (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258–2264CrossRefPubMed McKay JA, Murray LJ, Curran S et al. (2002) Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258–2264CrossRefPubMed
68.
Zurück zum Zitat Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787–2799CrossRef Mendelsohn J, Baselga J (2003) Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787–2799CrossRef
69.
Zurück zum Zitat Meropol NJ BJHJ (2003) Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 36: A256 Meropol NJ BJHJ (2003) Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 36: A256
70.
Zurück zum Zitat Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957–964CrossRefPubMed Moretta A (2002) Natural killer cells and dendritic cells: rendezvous in abused tissues. Nat Rev Immunol 2: 957–964CrossRefPubMed
71.
Zurück zum Zitat Motoki K, Mori E, Matsumoto A et al. (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11: 3126–3135CrossRefPubMed Motoki K, Mori E, Matsumoto A et al. (2005) Enhanced apoptosis and tumor regression induced by a direct agonist antibody to tumor necrosis factor-related apoptosis-inducing ligand receptor 2. Clin Cancer Res 11: 3126–3135CrossRefPubMed
72.
Zurück zum Zitat Ochsenbein AF, Zinkernagel RM (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21: 624–630CrossRefPubMed Ochsenbein AF, Zinkernagel RM (2000) Natural antibodies and complement link innate and acquired immunity. Immunol Today 21: 624–630CrossRefPubMed
73.
Zurück zum Zitat Ozawa S, Ueda M, Ando N et al. (1989) Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 43: 152–157CrossRefPubMed Ozawa S, Ueda M, Ando N et al. (1989) Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor. Int J Cancer 43: 152–157CrossRefPubMed
74.
75.
Zurück zum Zitat Perrotte P, Matsumoto T, Inoue K et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257–265PubMed Perrotte P, Matsumoto T, Inoue K et al. (1999) Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res 5: 257–265PubMed
76.
Zurück zum Zitat Pinto C, Di Fabio F, Siena S et al. (2006) Phase II Study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. Abstract No: 4031, ASCO 2006 Pinto C, Di Fabio F, Siena S et al. (2006) Phase II Study of cetuximab plus FOLFIRI as first-line treatment in patients with unresectable/metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma (FOLCETUX study): Preliminary results. Abstract No: 4031, ASCO 2006
77.
Zurück zum Zitat Pohle T, Brandlein S, Ruoff N et al. (2004) Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64: 3900–3906CrossRefPubMed Pohle T, Brandlein S, Ruoff N et al. (2004) Lipoptosis: tumor-specific cell death by antibody-induced intracellular lipid accumulation. Cancer Res 64: 3900–3906CrossRefPubMed
78.
Zurück zum Zitat Prenzel N, Fischer OM, Streit S et al. (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11–31CrossRefPubMed Prenzel N, Fischer OM, Streit S et al. (2001) The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8: 11–31CrossRefPubMed
79.
Zurück zum Zitat Prewett MC, Hooper AT, Bassi R et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994–1003PubMed Prewett MC, Hooper AT, Bassi R et al. (2002) Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8: 994–1003PubMed
80.
Zurück zum Zitat Pukac L, Kanakaraj P, Humphreys R et al. (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430–1441CrossRefPubMed Pukac L, Kanakaraj P, Humphreys R et al. (2005) HGS-ETR1, a fully human TRAIL-receptor 1 monoclonal antibody, induces cell death in multiple tumour types in vitro and in vivo. Br J Cancer 92: 1430–1441CrossRefPubMed
81.
Zurück zum Zitat Radinsky R, Risin S, Fan D et al. (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19–31PubMed Radinsky R, Risin S, Fan D et al. (1995) Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells. Clin Cancer Res 1: 19–31PubMed
82.
Zurück zum Zitat Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs (Suppl 1) 60: S15–S23 Raymond E, Faivre S, Armand JP (2000) Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy. Drugs (Suppl 1) 60: S15–S23
84.
Zurück zum Zitat Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49: 911–917PubMed Riesenberg R, Buchner A, Pohla H, Lindhofer H (2001) Lysis of prostate carcinoma cells by trifunctional bispecific antibodies (alpha EpCAM x alpha CD3). J Histochem Cytochem 49: 911–917PubMed
85.
Zurück zum Zitat Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580: 2879–2887CrossRefPubMed Roy H, Bhardwaj S, Yla-Herttuala S (2006) Biology of vascular endothelial growth factors. FEBS Lett 580: 2879–2887CrossRefPubMed
86.
Zurück zum Zitat Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526–2534CrossRefPubMed Ruf P, Lindhofer H (2001) Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody. Blood 98: 2526–2534CrossRefPubMed
87.
Zurück zum Zitat Saltz LB, Meropol NJ, Loehrer PJ Sr et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208CrossRefPubMed Saltz LB, Meropol NJ, Loehrer PJ Sr et al. (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22: 1201–1208CrossRefPubMed
88.
Zurück zum Zitat Shah M, Ilson D, Ramanathan R (2006; 2005) A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Proc Am Soc Clin Oncol 24: 314 s (A4025) Shah M, Ilson D, Ramanathan R (2006; 2005) A multicenter phase II study of irinotecan (CPT), cisplatin (CIS), and bevacizumab (BEV) in patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma. Proc Am Soc Clin Oncol 24: 314 s (A4025)
89.
Zurück zum Zitat Stacker SA, Achen MG, Jussila L et al. (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2: 573–583CrossRefPubMed Stacker SA, Achen MG, Jussila L et al. (2002) Lymphangiogenesis and cancer metastasis. Nat Rev Cancer 2: 573–583CrossRefPubMed
90.
Zurück zum Zitat Suntharalingam M, Dipetrillo T, Akerman P et al. (2006) Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. Abstract No: 4029, ASCO 2006 Suntharalingam M, Dipetrillo T, Akerman P et al. (2006) Cetuximab, paclitaxel, carboplatin and radiation for esophageal and gastric cancer. Abstract No: 4029, ASCO 2006
91.
Zurück zum Zitat Takahashi Y, Kitadai Y, Bucana CD et al. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968PubMed Takahashi Y, Kitadai Y, Bucana CD et al. (1995) Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 55: 3964–3968PubMed
92.
Zurück zum Zitat Thirion P, Michiels S, Pignon JP et al. (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22: 3766–3775CrossRefPubMed Thirion P, Michiels S, Pignon JP et al. (2004) Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis. J Clin Oncol 22: 3766–3775CrossRefPubMed
93.
Zurück zum Zitat Thuss-Patience PC, Kretzschmar A, Repp M et al. (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23: 494–501CrossRefPubMed Thuss-Patience PC, Kretzschmar A, Repp M et al. (2005) Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study. J Clin Oncol 23: 494–501CrossRefPubMed
94.
Zurück zum Zitat Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229–237CrossRefPubMed Tournigand C, Andre T, Achille E et al. (2004) FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22: 229–237CrossRefPubMed
95.
Zurück zum Zitat Trefzer U, Weingart G, Chen Y et al. (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85: 618–626CrossRefPubMed Trefzer U, Weingart G, Chen Y et al. (2000) Hybrid cell vaccination for cancer immune therapy: first clinical trial with metastatic melanoma. Int J Cancer 85: 618–626CrossRefPubMed
96.
Zurück zum Zitat Tyagi P (2005) Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5: 24–26PubMed Tyagi P (2005) Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 5: 24–26PubMed
97.
Zurück zum Zitat Valverde CM, Macarulla T, Casado E et al. (2006) Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol 59: 128–138PubMed Valverde CM, Macarulla T, Casado E et al. (2006) Novel targets in gastric and esophageal cancer. Crit Rev Oncol Hematol 59: 128–138PubMed
98.
Zurück zum Zitat Vanhoefer U, Tewes M, Rojo F et al. (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175–184CrossRefPubMed Vanhoefer U, Tewes M, Rojo F et al. (2004) Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor. J Clin Oncol 22: 175–184CrossRefPubMed
99.
Zurück zum Zitat Velders MP, Schreiber H, Kast WM (1998) Active immunization against cancer cells: impediments and advances. Semin Oncol 25: 697–706PubMed Velders MP, Schreiber H, Kast WM (1998) Active immunization against cancer cells: impediments and advances. Semin Oncol 25: 697–706PubMed
100.
Zurück zum Zitat Vollmers HP, Dammrich J, Ribbert H et al. (1995) Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550–558CrossRefPubMed Vollmers HP, Dammrich J, Ribbert H et al. (1995) Apoptosis of stomach carcinoma cells induced by a human monoclonal antibody. Cancer 76: 550–558CrossRefPubMed
101.
Zurück zum Zitat Vollmers HP, Hensel F, Hermann R et al. (1998) Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol Rep 5: 35–40PubMed Vollmers HP, Hensel F, Hermann R et al. (1998) Tumor-specific apoptosis induced by the human monoclonal antibody SC-1: a new therapeutical approach for stomach cancer. Oncol Rep 5: 35–40PubMed
102.
Zurück zum Zitat Vollmers HP, O’Connor R, Muller J et al. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471–2476PubMed Vollmers HP, O’Connor R, Muller J et al. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471–2476PubMed
103.
Zurück zum Zitat Vollmers HP, O’Connor R, Muller J et al. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471–2476PubMed Vollmers HP, O’Connor R, Muller J et al. (1989) SC-1, a functional human monoclonal antibody against autologous stomach carcinoma cells. Cancer Res 49: 2471–2476PubMed
104.
Zurück zum Zitat Vollmers HP, Zimmermann U, Krenn V et al. (1998) Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5: 549–552PubMed Vollmers HP, Zimmermann U, Krenn V et al. (1998) Adjuvant therapy for gastric adenocarcinoma with the apoptosis-inducing human monoclonal antibody SC-1: first clinical and histopathological results. Oncol Rep 5: 549–552PubMed
105.
Zurück zum Zitat Warren RS, Yuan H, Matli MR et al. (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789–1797PubMed Warren RS, Yuan H, Matli MR et al. (1995) Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis. J Clin Invest 95: 1789–1797PubMed
106.
Zurück zum Zitat Wilkinson NW, Black JD, Roukhadze E et al. (2004) Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8: 448–453CrossRefPubMed Wilkinson NW, Black JD, Roukhadze E et al. (2004) Epidermal growth factor receptor expression correlates with histologic grade in resected esophageal adenocarcinoma. J Gastrointest Surg 8: 448–453CrossRefPubMed
107.
Zurück zum Zitat Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23: 397–406PubMed Wils J (1996) The treatment of advanced gastric cancer. Semin Oncol 23: 397–406PubMed
108.
Zurück zum Zitat Wu X, Fan Z, Masui H et al. (1995) Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897–1905PubMed Wu X, Fan Z, Masui H et al. (1995) Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin. J Clin Invest 95: 1897–1905PubMed
Metadaten
Titel
Antikörpertherapie in klinischer und präklinischer Anwendung bei gastrointestinalen Karzinomen
verfasst von
Dr. A. Thalheimer
S. Braendlein
P. Vollmers
A. Thiede
D. Meyer
B. Illert
Publikationsdatum
01.03.2007
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 3/2007
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-007-1190-3

Weitere Artikel der Ausgabe 3/2007

Der Onkologe 3/2007 Zur Ausgabe

Einführung zum Thema

Onkologie quo vadis?

Neu im Fachgebiet Onkologie

Mit dem Alkoholentzug sinkt das Krebsrisiko

Wie die Ergebnisse einer Studie aus Frankreich nahelegen, kann sich das Risiko von alkoholabhängigen Menschen, an einem alkoholassoziierten Tumor zu erkranken, um rund 40% vermindern, wenn sie das Trinken reduzieren oder ganz einstellen.

Gemischte Befunde zur zielgerichteten Adjuvanz

23.07.2024 Melanom Nachrichten

Mit Blick auf rezidiv- und metastasenfreies Überleben bestätigen die finalen Ergebnisse der COMBI-AD-Studie die Wirksamkeit von Dabrafenib/Trametinib beim Stadium-III-Melanom. Die Effekte auf das Gesamtüberleben sind dagegen weniger klar.  

Verkürzte MRT bei dichtem Brustgewebe: Was bringen sequenzielle Scans?

21.07.2024 Mamma-MRT Nachrichten

Frauen mit dichtem Brustgewebe könnten zusätzlich zum regulären Mammografie-Screening von sequenziellen MRT-Untersuchungen mit verkürztem Protokoll (AB-MRT) profitieren, schlagen US-Radiologen vor.

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.